​

I-Mab (IMAB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IMAB Stock Forecast

I-Mab stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

IMAB Analyst Ratings

Buy

According to 2 Wall Street analysts, I-Mab's rating consensus is 'Buy'. The analyst rating breakdown for IMAB stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Sep 16, 2024Piper SandlerOverweightOverweightHold
Mar 18, 2024Piper SandlerOverweightOverweightHold
Aug 17, 2022NeedhamBuyBuyHold
Jun 07, 2022Piper SandlerOverweightOverweightHold

I-Mab's last stock rating was published by Piper Sandler on Sep 16, 2024. The company gave IMAB a "Overweight" rating, the same as its previous rate.

I-Mab Financial Forecast

I-Mab Revenue Forecast

Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23
Revenue-------------
Avg Forecast--$10.71M$10.71M-$49.99M$549.94M$239.97M$957.27M$957.27M-$5.45M$14.17M
High Forecast--$10.71M$10.71M-$49.99M$549.94M$239.97M$957.27M$957.27M-$5.45M$14.17M
Low Forecast--$10.71M$10.71M-$49.99M$549.94M$239.97M$957.27M$957.27M-$5.45M$14.17M
# Analysts--11-11111-11
Surprise %-------------

I-Mab's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IMAB's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

I-Mab EBITDA Forecast

Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23
# Analysts--11-11111-11
EBITDA-------------
Avg Forecast--$-4.05M$-4.05M-$-18.91M$-207.97M$-90.75M$-362.02M$-362.02M-$-2.06M$-5.36M
High Forecast--$-4.05M$-4.05M-$-18.91M$-207.97M$-90.75M$-362.02M$-362.02M-$-2.06M$-5.36M
Low Forecast--$-4.05M$-4.05M-$-18.91M$-207.97M$-90.75M$-362.02M$-362.02M-$-2.06M$-5.36M
Surprise %-------------

undefined analysts predict IMAB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than I-Mab's previous annual EBITDA (undefined) of $NaN.

I-Mab Net Income Forecast

Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23
# Analysts--11-11111-11
Net Income-------------
Avg Forecast$-87.31M$-87.31M--$-401.53M$-408.02M$145.51M$-387.00M$718.99M$718.99M$-274.23M$-181.81M$-484.95M
High Forecast$-87.31M$-87.31M--$-401.53M$-408.02M$145.51M$-387.00M$718.99M$718.99M$-274.23M$-181.81M$-484.95M
Low Forecast$-87.31M$-87.31M--$-401.53M$-408.02M$145.51M$-387.00M$718.99M$718.99M$-274.23M$-181.81M$-484.95M
Surprise %-------------

I-Mab's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IMAB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

I-Mab SG&A Forecast

Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23
# Analysts--11-11111-11
SG&A-------------
Avg Forecast--$66.28M$96.44M-$309.29M$3.40B$1.48B$5.92B$5.92B-$33.72M$87.65M
High Forecast--$66.28M$96.44M-$309.29M$3.40B$1.48B$5.92B$5.92B-$33.72M$87.65M
Low Forecast--$66.28M$96.44M-$309.29M$3.40B$1.48B$5.92B$5.92B-$33.72M$87.65M
Surprise %-------------

I-Mab's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IMAB last annual SG&A of $NaN (undefined).

I-Mab EPS Forecast

Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23
# Analysts--11-11111-11
EPS-------------
Avg Forecast$-1.07$-1.07--$-4.93$-5.01$1.79$-4.75$8.82$8.82$-3.36$-2.23$-5.95
High Forecast$-1.07$-1.07--$-4.93$-5.01$1.79$-4.75$8.82$8.82$-3.36$-2.23$-5.95
Low Forecast$-1.07$-1.07--$-4.93$-5.01$1.79$-4.75$8.82$8.82$-3.36$-2.23$-5.95
Surprise %-------------

According to undefined Wall Street analysts, I-Mab's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IMAB previous annual EPS of $NaN (undefined).

I-Mab Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
IMABI-Mab$0.95$35.003584.21%Buy
STTKShattuck Labs$1.15$12.00943.48%Hold
CGEMCullinan Oncology$11.49$34.00195.91%Buy
FHTXFoghorn Therapeutics$5.51$14.00154.08%Buy
ERASErasca$2.63$6.00128.14%Buy
APLSApellis Pharmaceuticals$34.53$70.80105.04%Buy
IMVTImmunovant$27.91$51.0082.73%Buy
AKROAkero Therapeutics$30.61$50.0063.35%Buy
DSGNDesign Therapeutics$6.25$9.6754.72%Buy
NRIXNurix Therapeutics$21.18$32.6754.25%Buy
LYELLyell Immunopharma$0.65$1.0053.85%Hold
ASNDAscendis Pharma$140.30$211.1450.49%Buy
BGNEBeiGene$179.06$267.3349.30%Buy
RVMDRevolution Medicines$45.16$65.6745.42%Buy
KYMRKymera Therapeutics$42.30$58.6038.53%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
KRYSKrystal Biotech$169.04$210.3324.43%Buy

IMAB Forecast FAQ

Is I-Mab a good buy?

Yes, according to 2 Wall Street analysts, I-Mab (IMAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of IMAB's total ratings.

What are I-Mab's analysts' financial forecasts?

I-Mab's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $962.72M (high $962.72M, low $962.72M), average EBITDA is $-364M (high $-364M, low $-364M), average net income is $262.96M (high $262.96M, low $262.96M), average SG&A $5.96B (high $5.96B, low $5.96B), and average EPS is $3.23 (high $3.23, low $3.23). IMAB's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $71.42M (high $71.42M, low $71.42M), average EBITDA is $-27.01M (high $-27.01M, low $-27.01M), average net income is $-810M (high $-810M, low $-810M), average SG&A $472.01M (high $472.01M, low $472.01M), and average EPS is $-9.934 (high $-9.934, low $-9.934).